Back to today’s briefing

Story perspectives

CHMP Backs Mirdametinib for Neurofibromatosis Treatment Approval

5/24/2025

29 6

Summary

Story summary

The CHMP has put its weight behind mirdametinib as a potential treatment for inoperable plexiform neurofibromas in both adults and children suffering from neurofibromatosis type 1. With a promising 41% response rate in adults and 52% in children from the ReNeu trial, the European Commission's decision on approval is eagerly awaited by Q3 2025.

1 of 1

Story summary

The CHMP has put its weight behind mirdametinib as a potential treatment for inoperable plexiform neurofibromas in both adults and children suffering from neurofibromatosis type 1. With a promising 41% response rate in adults and 52% in children from the ReNeu trial, the European Commission's decision on approval is eagerly awaited by Q3 2025.